In addition, human IL13Rα2-CAR-T therapy improves the GBM immune microenvironment and induces the activation of host immune cells that enhance the antitumor efficacy of CAR-T (Alizadeh et al., 2021). Here, IL13RA2 is linked to glioblastoma.